89bio, Inc. (ETNB) |
| 14.84 0 (0%) 10-30 16:00 |
| Open: | 14.84 |
| High: | 14.84 |
| Low: | 14.84 |
| Volume: | 38,511,212 |
| Market Cap: | 2,201(M) |
| PE Ratio: | -4.02 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 33.33 |
| Resistance 1: | 28.54 |
| Pivot price: | 23.71 |
| Support 1: | 22.89 |
| Support 2: | 19.39 |
| 52w High: | 15.06 |
| 52w Low: | 4.16 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Financials
| EPS | -0.100 |
| Book Value | 2.760 |
| PEG Ratio | 0.99 |
| Gross Profit | 7.247 |
| Profit Margin (%) | -1.15 |
| Operating Margin (%) | 4.27 |
| Return on Assets (ttm) | 1.2 |
| Return on Equity (ttm) | -3.7 |
Company news
Thu, 14 May 2026
89bio stock (US28252C1099): Delisting amid liquidation process - AD HOC NEWS
Thu, 30 Oct 2025
Roche Holdings completes acquisition of 89bio and delists company from Nasdaq - Investing.com
Tue, 30 Sep 2025
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal - Yahoo Finance
Fri, 19 Sep 2025
89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger - Yahoo Finance
Thu, 18 Sep 2025
Why Did 89bio Stock Nearly Double In Value Today? - Stocktwits
Thu, 18 Sep 2025
Roche enters into a definitive merger agreement to acquire - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
